Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 20,000,000
Countries
Sector(s)
Denmark : € 20,000,000
Industry : € 20,000,000
Signature date(s)
20/12/2024 : € 20,000,000
Link to source

Summary sheet

Release date
2 January 2025
Status
Reference
Signed | 20/12/2024
20230605
Project name
Promoter - financial intermediary
NORLASE RDI (IEU LS)
NORLASE APS
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 20 million
EUR 44 million
Location
Sector(s)
Description
Objectives

The project supports the development and market access of innovative portable ophthalmic lasers to diagnose and treat causes of vision loss and blindness. Key project elements are novel eye laser technologies, including expansion of production facilities.

The project will support the promoter's investments in Research, Development, and Innovation (RDI) to advance its new eye laser treatment as well as other innovative medical devices based on novel laser technology. The project also includes capital expenditure (capex) and market access costs.

Additionality and Impact

The project is aligned with the InvestEU objective of promoting research, development and innovation. The purpose of the loan is to provide direct equity-type financing to an innovative medtech company developing and commercialising an innovative portable ophthalmic lasers to treat some of the most common causes of vision loss and blindness, including: Diabetic Retinopathy, Glaucoma, Age-related Macular Degeneration (AMD), Retinal tears and retinopathy of Prematurity (ROP). 

By supporting the Promoter, the EIB enables the generation of European scientific knowledge and know-how while preserving and expanding highly skilled employment opportunities in Europe and is expected to enhance market competition within the medical laser devices sector. Currently, the Company does not have access to either non-dilutive or to long-term debt funding sources. The financing structure is adjusted to the investment needs of the Company, with a long tenor and deferred interest, minimising cash outflows. By contributing to the cash runway, EIB financing is expected to allow the company to accelerate its development. The project would not have been carried out to the same extent by the EIB without InvestEU support.

Environmental aspects
Procurement

The project consists of operative expenditures for RDI on laser based treatments and diagnosis solutions as well as deployment of technology to increase the promoter's manufacturing capacity inside an existing site. The project's activities are not listed in any of the Annexes of EIA Directive 2011/92/EU amended by Directive 2014/52/EU. The project's activities contribute in full to the Bank's Climate Action and Environmental Sustainability (CA&ES) cross-cutting objective.

The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Milestone
Under appraisal
Approved
Signed
9 December 2024
20 December 2024
Related projects
Link to source
Summary sheet

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - NORLASE RDI (IEU LS)
Publication Date
8 Jan 2025
Document language
Main Topic
Lending
Document Number
177445456
Document Focus
Environmental Information
Project Number
20230605
Sector(s)
Regions
Countries
Publicly available
Download now

News & Stories

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications